ATXN3 and Machado-Joseph disease: We have therefore assessed the variation in ATXN3 UTRs using blood samples of molecularly confirmed MJD patients from the Azorean cohort and predicted their functional impact, identifying variants whose presence/absence contributed to modulation of onset ([71,72]).